Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Integrating Injectable LEN PrEP Delivery in Maternal and Child Health Clinics to Prevent HIV in Pregnant and Postpartum Women

Award Number: R01HD123957
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/14/2026
PERIOD OF PERFORMANCE END DATE: 08/31/2031

Group Awards By:

View Award Description

Integrating Injectable LEN PrEP Delivery in Maternal and Child Health Clinics to Prevent HIV in Pregnant and Postpartum Women - ABSTRACT In high HIV prevalence regions, women are at elevated risk for HIV during pregnancy and breastfeeding, and are priority population for HIV prevention. Despite widespread availability of oral HIV preexposure prophylaxis (PrEP), utilization is low especially during postpartum when more than 50% of young African women on PrEP discontinue due to daily pill adherence and stigma challenges. Twice-yearly injectable Lenanacapvir (LEN) PrEP was 100% efficacious in clinical trials among women and was safe and well-tolerated in pregnancy. LEN is recommended by the FDA and WHO as an additional PrEP option for pregnant/postpartum women at elevated HIV risk, while calling for additional safety surviellence during implementation. For pregnant women who choose LEN PrEP, three doses initiated in early pregnancy can offer coverage up to at least 6 months postpatum, highlighting the potential to significantly avert primary HIV infection and vertical transmission during periods of elevated risk. But LEN PrEP impact will depend on access and how well opportunity costs and health-system barriers can be navigated by clients. Maternal and child health (MCH) clinics offer a trusted and routinely accessed setting for many pregnant and postpartum women to learn about and obtain PrEP. Our team pioneered oral PrEP delivery models in routine MCH clinics. We established feasibility, demonstrated safety, and identified barriers to integrating oral PrEP in MCH clinics. We are well to positioned to define effective models to deliver LEN delivery for pregnancy and breastfeeding women and additional surveillance of perinatal exposure outcomes. Building on our successful work with oral PrEP in MCH clinics and in collaboration with the Kenya ministry of health (MOH), we propose a hybrid pragmatic stepped-wedge cluster randomized trial to test sustainable effective delivery models and demonstrate impact of LEN PrEP in 12 real-world MCH clinics in two HIV high incidence counties prioritized for LEN roll-out in Kenya. We will rigorously evaluate impact of adding LEN PrEP as an available PrEP option (oral F/TDF or LEN) on uptake, HIV prevention coverage, and new HIV infections averted among 1200 pregnant and postpartum women at elevated HIV risk (Aim 1). In Aim 2, we will enroll and follow a subset of pregnant women who choose LEN PrEP (n=200) in a nested cohort to robustly evaluate prenatal and post-natal LEN PrEP exposure and the frequency of adverse birth and infant outcomes up to at least child's 1st birth day. In parallel with Aim 1, we will evaluate implementation outcomes and assess impact of integration on existing workflows, clinic, provider, and client-level factors, including client experiences, PrEP product choice and switch, and preferences (Aim 3). These innovative studies will demonstrate significant public health impact and robust extended safety outcomes for LEN PrEP in pregnancy to advance scale up where it is needed most, while efficiently generating effective and sustainable real-world LEN PrEP implementation models that can be quickly adapted to communities most affected by HIV globally and in the US.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $734,438 )
2026	2026	UNIVERSITY OF WASHINGTON	4333 BROOKLYN AVE NE	SEATTLE	WA	98195	KING	USA	Child Health and Human Development Extramural Research	000	1	9/14/2026	NEW	$734,438
														Subtotal = $734,438

Grand Total All Awards = $734,438

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Integrating Injectable LEN PrEP Delivery in Maternal and Child Health Clinics to Prevent HIV in Pregnant and Postpartum Women

Award Number: R01HD123957

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/14/2026

PERIOD OF PERFORMANCE END DATE: 08/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer